APREA THERAPEUTICS ANNOUNCES INTERIM RESULTS FROM THE ONGOING FIRST-IN-HUMAN PHASE 1 STUDY OF WEE1 INHIBITOR APR-1051 IN PATIENTS WITH ADVANCED SOLID TUMORS (ACESOT-1051) AT THE 38TH EORTC-NCI-AACR SYMPOSIUM IN BARCELONA

Reuters · 1d ago

Please log in to view news